Results 141 to 150 of about 86,629 (276)

A RETROSPECTIVE ANALYSIS OF THE INCIDENCE OF POLYNEUROPATHY IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH BORTEZOMIB-CONTAINING COURSES [PDF]

A.P. Maltsev, N.V. Selyanina
openalex   +1 more source

Cryoglobulinemia: An update on classification, pathophysiology, clinical presentation, and management

Journal of Internal Medicine, Volume 299, Issue 2, Page 196-215, February 2026.
Abstract Cryoglobulinemia (CG) is defined by the presence of serum immunoglobulins that precipitate below 37°C and redissolve upon rewarming. It is classified into three types based on immunoglobulin composition. Type I, a rare form, involves monoclonal IgM or IgG and is linked to lymphoproliferative disorders.
Anna Linda Zignego, Laura Gragnani, Marcella Visentini, Riccardo Bomben, Luca Arcaini, Clodoveo Ferri, Valter Gattei, Cesare Mazzaro   +7 more
wiley   +1 more source

Bortezomib

Indian Journal of Medical and Paediatric Oncology, 2010
openaire   +4 more sources

Data from Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy

, 2023
John Wright
openalex   +1 more source

Design and Synthesis of Boron‐Containing Noncanonical Amino Acids With Enhanced Stability and Solubility

European Journal of Organic Chemistry, Volume 29, Issue 3, January 22, 2026.
We report a new class of boron‐containing noncanonical amino acids with improved aqueous solubility and stability. Structural tuning around the boron center enhances biological compatibility, and unique fluorescence properties suggest applications in protein engineering and biosensing, advancing boron‐based tools for chemical biology and drug discovery.
Eunsol Jo, Hyojung Ahn, Guldana Issabayeva, On‐Yu Kang, Jungtaek Kim, Young‐Chul Song, Ik Jae Lee, Hei‐Cheul Jeung, Ji Young Hyun, Seong Jun Park, Hwan Jung Lim   +10 more
wiley   +1 more source

Dihydrolipoamide dehydrogenase (DLD) is a novel molecular target of bortezomib

Cell Death and Disease
Proteasome inhibitors (PIs), such as bortezomib and calfizomib, were backbone agents in the treatment of multiple myeloma (MM). In this study, we investigated bortezomib interactors in MM cells and identified dihydrolipoamide dehydrogenase (DLD) as a ...
Yu Feng, Hongmei Luo, Jingcao Huang, Yue Zhang, Jingjing Wen, Linfeng Li, Ziyue Mi, Qianwen Gao, Siyao He, Xiang Liu, Xinyu Zhai, Xin Wang, Li Zhang, Ting Niu, Yuhuan Zheng   +14 more
doaj   +1 more source

PB2104 INHIBITION OF NUCLEOLIN REVERSED BORTEZOMIB RESISTANCE VIA THE REGULATION OF NF‐κB PATHWAY IN MULTIPLE MYELOMA CELLS

, 2019
Jianda Hu, Wenge Liu, Tsung‐Ming Yang, Y. Chen   +3 more
openalex   +1 more source

Direct and Natural Killer Cell-Mediated Antitumor Effects of Low-Dose Bortezomib in Hepatocellular Carcinoma [PDF]

, 2008
Sorin Armeanu, Matthias Krusch, Katrin M. Baltz, Thomas S. Weiß, Irina Smirnow, Alexander Steinle, Ulrich M. Lauer, Michael Bitzer, Helmut R. Salih   +8 more
openalex   +1 more source

Epigenetic reprogramming in multiple myeloma—Challenges and opportunities

International Journal of Cancer, Volume 158, Issue 2, Page 423-432, 15 January 2026.
Abstract In cancer, mutational processes act in concert with epigenetic reprogramming to endow malignant cells with hallmark properties that underpin tumorigenesis. Compared with the relatively rigid and slow processes of genetic evolution, the plastic nature of chromatin enables cells to adapt to a changing environment more rapidly.
Subhasree Kumar, Lev M. Kats, Emily Gruber   +2 more
wiley   +1 more source

Chemoresistance of PRAME-expressing melanoma cell can be resolved with help of bortezomib

, 2019
V. A. Misyurin, Daria Kalenichenko, A. A. Rudakova, Yu. P. Finashutina, Н. А. Лыжко, В. В. Тихонова, Л. А. Кесаева, О. Н. Солопова, Anna Misyurina, А. Н. Великанов, М. А. Барышникова, A. V. Misyurin   +11 more
openalex   +2 more sources